Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Eiger BioPharmaceuticals stock
Learn how to easily invest in Eiger BioPharmaceuticals stock.
Eiger BioPharmaceuticals Inc is a biotechnology business based in the US. Eiger BioPharmaceuticals shares (EIGR) are listed on the NASDAQ and all prices are listed in US Dollars. Eiger BioPharmaceuticals employs 34 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Eiger BioPharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EIGR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Eiger BioPharmaceuticals stock price (NASDAQ: EIGR)Use our graph to track the performance of EIGR stocks over time.
Eiger BioPharmaceuticals shares at a glance
|Latest market close||$4.72|
|52-week range||$4.66 - $13.49|
|50-day moving average||$6.28|
|200-day moving average||$7.52|
|Wall St. target price||$25.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.92|
Buy Eiger BioPharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Eiger BioPharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Eiger BioPharmaceuticals price performance over time
|1 week (2022-01-10)||-2.68%|
|1 month (2021-12-17)||-16.31%|
|3 months (2021-10-15)||-27.94%|
|6 months (2021-07-16)||-40.40%|
|1 year (2021-01-15)||-57.17%|
|2 years (2020-01-17)||-66.50%|
|3 years (2019-01-17)||13.54|
|5 years (2017-01-17)||12.25|
Eiger BioPharmaceuticals financials
|Revenue TTM||$8.8 million|
|Gross profit TTM||$0|
|Return on assets TTM||-32.92%|
|Return on equity TTM||-33.94%|
|Market capitalisation||$162.1 million|
TTM: trailing 12 months
Eiger BioPharmaceuticals share dividends
We're not expecting Eiger BioPharmaceuticals to pay a dividend over the next 12 months.
Have Eiger BioPharmaceuticals's shares ever split?
Eiger BioPharmaceuticals's shares were split on a 1:15 basis on 22 March 2016. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eiger BioPharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Eiger BioPharmaceuticals shares which in turn could have impacted Eiger BioPharmaceuticals's share price.
Eiger BioPharmaceuticals share price volatility
Over the last 12 months, Eiger BioPharmaceuticals's shares have ranged in value from as little as $4.66 up to $13.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eiger BioPharmaceuticals's is 1.2585. This would suggest that Eiger BioPharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Eiger BioPharmaceuticals overview
Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California. .
Eiger BioPharmaceuticals in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Stocks That Hit 52-Week Lows On Wednesday
Eiger BioPharmaceuticals Inc Shares Close in on 52-Week Low - Market Mover
Frequently asked questionsWhat percentage of Eiger BioPharmaceuticals is owned by insiders or institutions?
Currently 1.222% of Eiger BioPharmaceuticals shares are held by insiders and 68.966% by institutions. How many people work for Eiger BioPharmaceuticals?
Latest data suggests 34 work at Eiger BioPharmaceuticals. When does the fiscal year end for Eiger BioPharmaceuticals?
Eiger BioPharmaceuticals's fiscal year ends in December. Where is Eiger BioPharmaceuticals based?
Eiger BioPharmaceuticals's address is: 2155 Park Boulevard, Palo Alto, CA, United States, 94306 What is Eiger BioPharmaceuticals's ISIN number?
Eiger BioPharmaceuticals's international securities identification number is: US28249U1051 What is Eiger BioPharmaceuticals's CUSIP number?
Eiger BioPharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 15117E107
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert